Look­ing to an IPO? Rhythm rais­es $41M to pay for piv­otal tri­als

In a move fes­tooned with all the trap­pings of a pre-IPO deal, Boston-based Rhythm has come in with a $41 mil­lion fi­nanc­ing from a big syn­di­cate that in­cludes a few no­table crossover in­vestors.

Deer­field Man­age­ment, Ipsen, Or­biMed, MPM Cap­i­tal, New En­ter­prise As­so­ciates, Pfiz­er Ven­ture In­vest­ments, Third Rock Ven­tures, and an undis­closed pub­lic health­care in­vest­ment fund all stepped in to back the mez­za­nine round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER